Bayer trumpets $1bn CRISPR deal with Mammoth Bio
pharmaphorum
JANUARY 10, 2022
Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences.
Gene Editing Genetic Disease Genetics Licensing 
52 
4 Life Sciences Trends for 2023
XTalks
DECEMBER 29, 2022
In 2022 alone, the US regulator approved four new gene therapies, showing the high interest in getting these therapies to market. In 2023, a number of gene therapies are expected to get the FDA green light. Given their precise targeting, gene therapies have largely been focused on oncology indications followed by rare genetic diseases.
Advances in neuroscience drug discovery
Drug Discovery World
FEBRUARY 22, 2024
For diseases as serious and debilitating for patients and their families as leukodystrophies, learning about such advances in knowledge carries a great deal of hope, which IRCM warmly welcomes,” adds Dr Jean-François Côté, the IRCM’s President and Scientific Director.
Let's personalize your content